Menges M - Search Results

1

Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity.

Voigtländer C, Rössner S, Cierpka E, Theiner G, Wiethe C, Menges M, Schuler G, Lutz MB. Voigtländer C, et al. Among authors: menges m. J Immunother. 2006 Jul-Aug;29(4):407-15. doi: 10.1097/01.cji.0000210081.60178.b4. J Immunother. 2006. PMID: 16799336

2

Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity.

Menges M, Rössner S, Voigtländer C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, Lutz MB. Menges M, et al. J Exp Med. 2002 Jan 7;195(1):15-21. doi: 10.1084/jem.20011341. J Exp Med. 2002. PMID: 11781361 Free PMC article.

3

Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF.

Lutz MB, Schnare M, Menges M, Rössner S, Röllinghoff M, Schuler G, Gessner A. Lutz MB, et al. Among authors: menges m. J Immunol. 2002 Oct 1;169(7):3574-80. doi: 10.4049/jimmunol.169.7.3574. J Immunol. 2002. PMID: 12244147

4

Minor role of bystander tolerance to fetal calf serum in a peptide-specific dendritic cell vaccine model against autoimmunity: comparison with serum-free cultures.

Röner S, Zinser E, Menges M, Wiethe C, Littmann L, Hänig J, Steinkasserer A, Lutz MB. Röner S, et al. Among authors: menges m. J Immunother. 2008 Sep;31(7):656-64. doi: 10.1097/CJI.0b013e31818283ef. J Immunother. 2008. PMID: 18600179

5

IL-4 supports the generation of a dendritic cell subset from murine bone marrow with altered endocytosis capacity.

Menges M, Baumeister T, Rössner S, Stoitzner P, Romani N, Gessner A, Lutz MB. Menges M, et al. J Leukoc Biol. 2005 Apr;77(4):535-43. doi: 10.1189/jlb.0804473. Epub 2004 Dec 23. J Leukoc Biol. 2005. PMID: 15618296

6

Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro.

Lutz MB, Kukutsch NA, Menges M, Rössner S, Schuler G. Lutz MB, et al. Among authors: menges m. Eur J Immunol. 2000 Apr;30(4):1048-52. doi: 10.1002/(SICI)1521-4141(200004)30:4<1048::AID-IMMU1048>3.0.CO;2-W. Eur J Immunol. 2000. PMID: 10760792 Free article.

7

Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.

Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Faramand RG, et al. Among authors: menges m. Blood Cancer Discov. 2024 Mar 1;5(2):106-113. doi: 10.1158/2643-3230.BCD-23-0056. Blood Cancer Discov. 2024. PMID: 38194367

8

Vitamin E-enriched medium cross-linked polyethylene in total knee arthroplasty (VIKEP): clinical outcome, oxidation profile, and wear analysis in comparison to standard polyethylene-study protocol for a randomized controlled trial.

Maier K, Selig M, Haddouche A, Haunschild M, Hauschild O, Khalili I, Kirschberg J, Lutter C, Menges M, Mertl P, Niemeier A, Rubens-Duval B, Mittelmeier W. Maier K, et al. Among authors: menges m. Trials. 2024 Jan 5;25(1):27. doi: 10.1186/s13063-023-07811-1. Trials. 2024. PMID: 38183062 Free PMC article.

9

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.

Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Freeman CL, et al. Among authors: menges m. Clin Cancer Res. 2023 Nov 14;29(22):4575-4585. doi: 10.1158/1078-0432.CCR-22-3987. Clin Cancer Res. 2023. PMID: 37735756

10

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.

Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. Stein-Thoeringer CK, et al. Among authors: menges m. Nat Med. 2023 Apr;29(4):906-916. doi: 10.1038/s41591-023-02234-6. Epub 2023 Mar 13. Nat Med. 2023. PMID: 36914893 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page